- Home
- SER vs OPTN Comparison
SER vs OPTN Comparison
Compare SER & OPTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SER
- OPTN
- Stock Information
- Founded
- SER 2017
- OPTN 2010
- Country
- SER United States
- OPTN United States
- Employees
- SER N/A
- OPTN N/A
- Industry
- SER Biotechnology: Pharmaceutical Preparations
- OPTN Biotechnology: Pharmaceutical Preparations
- Sector
- SER Health Care
- OPTN Health Care
- Exchange
- SER Nasdaq
- OPTN Nasdaq
- Market Cap
- SER 47.5M
- OPTN 55.4M
- IPO Year
- SER 2018
- OPTN 2017
- Fundamental
- Price
- SER $5.18
- OPTN $9.15
- Analyst Decision
- SER Strong Buy
- OPTN Hold
- Analyst Count
- SER 1
- OPTN 3
- Target Price
- SER $11.00
- OPTN $9.00
- AVG Volume (30 Days)
- SER 10.4K
- OPTN 172.3K
- Earning Date
- SER 05-24-2025
- OPTN 03-26-2025
- Dividend Yield
- SER N/A
- OPTN N/A
- EPS Growth
- SER N/A
- OPTN N/A
- EPS
- SER N/A
- OPTN N/A
- Revenue
- SER $56,000.00
- OPTN $78,226,000.00
- Revenue This Year
- SER N/A
- OPTN $13.42
- Revenue Next Year
- SER N/A
- OPTN $38.54
- P/E Ratio
- SER N/A
- OPTN N/A
- Revenue Growth
- SER N/A
- OPTN 10.20
- 52 Week Low
- SER $3.81
- OPTN $4.82
- 52 Week High
- SER $14.57
- OPTN $22.05
- Technical
- Relative Strength Index (RSI)
- SER 57.34
- OPTN 81.01
- Support Level
- SER $4.60
- OPTN $9.12
- Resistance Level
- SER $5.82
- OPTN $9.35
- Average True Range (ATR)
- SER 0.40
- OPTN 0.25
- MACD
- SER 0.10
- OPTN 0.24
- Stochastic Oscillator
- SER 62.79
- OPTN 89.46
About SER Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers.
About OPTN OptiNose Inc.
OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.